Acrux Ltd has released a press release.
Acrux: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Quarterly Activities/Appendix 4C Cash Flow Report
- Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
- AGM Presentation and Address
- Acrux receives $0.4m advance on FY26 R&D Tax Incentive
- Received $3.04m RDTI rebate for FY25
Later from Acrux
- Acrux receives $0.55m advance on FY26 R&D Tax Incentive
- Acrux strategy focuses on Female Testosterone for low libido
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux raises $1.6 million via Share Placement
- Capital Gains Tax exemptions remain in place for Acrux
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux